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GlioblastomaSuccess in developing therapeutic approaches to target brain tumor-associated inﬂammation in patients
has been limited. Given that the inﬂammatory microenvironment is a hallmark signature of solid tumor
development, anti-inﬂammatory targeting strategies have been envisioned as preventing glioblastoma initiation
or progression. Consumption of foods from plant origin is associated with reduced risk of developing cancers, a
chemopreventive effect that is, in part, attributed to their high content of phytochemicals with potent anti-
inﬂammatory properties. We explored whether luteolin, a common ﬂavonoid in many types of plants, may
inhibit interleukin (IL)-1β function induction of the inﬂammation biomarker cyclooxygenase (COX)-2. We
found that IL-1β triggeredCOX-2 expression inU-87 glioblastoma cells and synergizedwith luteolin to potentiate
or inhibit that induction in a biphasic manner. Luteolin pretreatment of cells inhibited IL-1β-mediated
phosphorylation of inhibitor of κB, nuclear transcription factor-κB (NF-κB) p65, extracellular signal-regulated
kinase-1/2, and c-Jun amino-terminal kinase in a concentration-dependent manner. Luteolin also inhibited
AKT phosphorylation and survivin expression, while it triggered both caspase-3 cleavage and expression of
glucose-regulated protein 78. These effects were all potentiated by IL-1β, in part through increased nuclear
translocation of NF-κB p65. Finally, luteolin was able to reduce IL-1 receptor gene expression, and treatment
with IL-1 receptor antagonist or gene silencing of IL-1 receptor prevented IL-1β/luteolin-induced COX-2
expression. Our results document a novel adaptive cellular response to luteolin, which triggers anti-survival
and anti-inﬂammatory mechanisms that contribute to the chemopreventive properties of this diet-derived
molecule.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Glioblastomamultiforme is themost common glioma and is a highly
malignant primary brain tumor, associated with a poor survival rate [1].
This glioma is known for its invasiveness and high resistance to
standard treatments of chemotherapy and radiotherapy [2,3]. The
tumor microenvironment regulates glioblastoma development
and progression and, among the pool of inﬂammatory cytokines,
elevated levels of interleukin (IL)-1β are believed to contribute toervous system; COX-2, cycloox-
lum; ERK, extracellular signal-
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ceptor type I; JNK, c-Jun amino-
e; NF-κB, nuclear transcription
éculaire, Université duQuébec à
H3C 3P8, Canada. Tel.: +1 514
orhane@uqam.ca (B. Annabi).glioblastoma cell proliferation and invasion [4–6]. Thus, blocking
the pro-inﬂammatory activity of IL-1βwould be useful in controlling
the invasiveness of glioblastoma cells.
Cyclooxygenases (COXs) catalyze the synthesis of prostaglandins
from arachidonic acid and include the constitutive isoform COX-1, the
inducible isoform COX-2 and a splice variant COX-3 [7]. COX-2, which
is regulated by various growth factors and cytokines such as IL-1β [8],
is a crucial target for the control of tumors associated with chronic
inﬂammation [9]. Increased COX-2 has been detected in a variety of
human malignant tumors including glioblastomas, in which its expres-
sion correlated with the histopathological grade of gliomas [10]. High
levels of COX-2 have been correlated with higher proliferation rates of
tumors and shorter patient survival times [11]. There is also clear evi-
dence of the positive effects of COX-2 inhibitors, including nonsteroidal
anti-inﬂammatory drugs, against a variety of tumors, which exert che-
mopreventive activities [12].
The nuclear transcription factor-κB (NF-κB) is one of the major
transcription factors associated with cancer development [13]. In
response to different stimuli, mainly cytokines, glioblastoma cells
exhibit elevated levels of NF-κB activity which contribute signiﬁcantly
to tumor progression [14]. Moreover, it was reported that NF-κB
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sponse to IL-1β [15]. Binding of IL-1β to its type 1 receptor (IL-1R1) ac-
tivates a cascade of phosphorylation that results in NF-κB activation
[16]. NF-κB is a protein complex consisting of a 65-kDa DNA binding
subunit (Rel A) and an associated 50-kDa protein which, in the classical
NF-κB pathway, is maintained in the cytoplasm in an inactive state by a
protein complex called inhibitor of κB (IκB) [17]. Once phosphorylated
by the IκB kinases (IKKs), IκB then allows the p65 and p50 subunits of
NF-κB to translocate to the nucleus and to bind to the κB recognition
sites located in the promoter regions of various NF-κB-regulated
genes such as COX-2 [18]. Deregulation of the NF-κB signaling pathway
contributes to enhanced glioblastoma cell survival, proliferation, cell
cycle progression and chemoresistance; it therefore represents an at-
tractive therapeutic target [19–21].
Numerous studies have linked abundant consumption of foods from
plant origins with decreased risk of developing various cancers [22], a
chemopreventive effect that is related to the high content of several
phytochemicals with potent anticancer and anti-inﬂammatory proper-
ties [23]. Among these, luteolin (3′,4′,5,7-tetrahydroxyﬂavone), a ﬂavo-
noid found at high levels in common fruits, vegetables and herbs such as
green peppers, olive oil, parsley, celery, thyme, broccoli, cabbages, and
chamomile tea [24,25], possesses a variety of neuroprotective [26], anti-
cancer [24] and anti-inﬂammatory [27] properties. For instance, luteolin
was demonstrated to antagonize phorbol 12-myristate 13-acetate
(PMA)-induced COX-2 in human brain endothelial cells [28] and to in-
hibit tumor necrosis factor (TNF)-α-induced COX-2 expression by
down-regulating the transactivation of NF-κB and activator protein-1
(AP-1) in JB6mouse epidermis cells [29]. However, the effect of luteolin
on the pro-inﬂammatory cytokine IL-1β-mediated induction of COX-2
has never been investigated. Here, we report for the ﬁrst time anti-IL-
1β effects of luteolin on the NF-κB-mediated transcriptional regulation
of COX-2 expression in U-87 glioblastoma cells.
2. Materials and methods
2.1. Materials
Luteolin (purity ≥ 99%) was purchased from Extrasynthese (Lyon,
France). Human recombinant IL-1β and human recombinant IL-1Ra
were obtained from R&D Systems (Minneapolis, MN). The MEK inhibi-
tor U0126 and the JNK inhibitor SP60012 were from Calbiochem (La
Jolla, CA). Electrophoresis reagents were purchased from Bio-Rad (Mis-
sissauga, ON). The anti-ERK (extracellular signal-regulated kinase 1 and
2) (K-23) polyclonal antibody was from Santa Cruz Biotechnologies
(Santa Cruz, CA). The monoclonal antibody against GAPDH (glyceralde-
hyde 3-phosphate dehydrogenase) was from Advanced Immunochem-
ical Inc. (Long Beach, CA). The Alexa Fluor® 488 donkey anti-rabbit IgG
antibodywas purchased from Invitrogen (Carlsbad, NM). Antibodies for
AKT, Bip/GRP78 (glucose-regulated protein 78), caspase-3, cleaved-
caspase-3, IκB, lamin A/C, NF-κB p65, SAPK/JNK (c-Jun amino-terminal
kinase), survivin, phospho-AKT, phospho-NF-κB p65, phospho-SAPK/
JNK polyclonal antibodies and phospho-ERK and phospho-IκB mono-
clonal antibodies were from Cell Signaling Technology (Beverly, MA).
The anti-COX-2 monoclonal antibody was from BD Transduction
Laboratories™ (Franklin Lakes, NJ). Anti-mouse and anti-rabbit horse-
radish peroxidase (HRP)-linked secondary antibodies were purchased
from Jackson ImmunoResearch Laboratories (West Grove, PA) and
enhanced chemiluminescence (ECL) reagentswere fromDenville Scien-
tiﬁc Inc. (Metuchen,NJ).Micro bicinchoninic acid protein assay reagents
were from Thermo Scientiﬁc (Rockford, IL). All other reagents were
from Sigma-Aldrich (Oakville, ON).
2.2. Cell culture
A human glioblastoma cell line (U-87 MG) was purchased from the
American Tissue Culture Collection (HTB-14™) and maintained inmodiﬁed Eagle'sMinimumEssentialMedium (Wisent, 320-036-CL) con-
taining 10% calf serum (HyClone Laboratories, SH30541.03), 1 mM sodi-
um pyruvate (Sigma-Aldrich, P2256), 2 mM L-glutamine, 100 units/mL
penicillin and 100 μg/mL streptomycin (Wisent, 450-202-EL). Cells
were cultured at 37 °C under a humidiﬁed 95%–5% (v/v) mixture of air
and CO2. Cells were treated with vehicle (0.1% DMSO) or with luteolin
and stimulated with IL-1β. All cellular assays were conducted at 85%
conﬂuence.
2.3. Western blot analysis
U-87 MG cells were serum-starved in the presence of luteolin,
U0126 (10 μM) or SP60012 (10 μM) for 24 h. To study the effects of
these molecules on protein expression of COX-2, caspase-3, cleaved
caspase-3 or survivin, cells were co-treated with one of these molecules
and 50 ng/mL IL-1β or 1 μMPMA for 24 h. To study the phosphorylation
status of AKT, IκB, NF-κB p65, ERK and JNK, IL-1βwas added to the cells
for 5 min after the treatment with luteolin for 24 h. Cells were then
washed once with ice-cold phosphate-buffered saline (PBS) containing
1 mM each of NaF and Na3VO4 and were incubated in the same buffer
solution for 30 min at 4 °C. The cells were solubilized on ice in lysis
buffer [150 mM NaCl, 10 mM Tris–HCl, pH 7.4, 1 mM EDTA, 1 mM
ethyleneglycol-O, O′-bis(2-aminoethyl)-N,N,N′,N′-tetraacetic acid
(EGTA), 0.5% (vol/vol) Nonidet P-40 and 1% (vol/vol) Triton X-100]. To
study the translocation of NF-κB p65 into the nucleus, nuclear protein
extracts from U-87 MG cells were isolated using the NE-PER Nuclear
and cytoplasmic extraction kit (Pierce, Rockford, IL). The resulting ly-
sates or nuclear extracts (25 μg protein) were solubilized in Laemmli
sample buffer [125 mM Tris–HCl (pH 6.8), 20% glycerol, 4% SDS, 10%
β-mercaptoethanol, and 0.00125% bromophenol blue], boiled for
4 min, and separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). After electrophoresis, proteinswere trans-
ferred to polyvinylidene diﬂuoride (PVDF) membranes which were
then blocked 1 h at 4 °C with 5% nonfat dry milk in Tris-buffered sa-
line/Tween 20 (TBS-T; 147 mM NaCl, 20 mM Tris–HCl, pH 7.5, and
0.1% Tween 20).Membraneswere furtherwashed in TBS-T and incubat-
ed overnight with the primary antibody in TBS-T containing 3% bovine
serum albumin (BSA) and 0.01% sodium azide (NaN3), followed by a
1 h incubation with HRP-conjugated anti-mouse or anti-rabbit anti-
bodies in TBS-T containing 5% nonfat dry milk. Immunoreactive materi-
al was visualized with an ECL detection system. The immunoreactive
bands were quantiﬁed with ImageJ software (NIH).
2.4. Total RNA isolation, cDNA synthesis and real-time quantitative PCR
Total RNAwas extracted from U-87MGmonolayers using TRIzol re-
agent (Life Technologies, Gaithersburg,MD). For cDNA synthesis, 1 μg of
total RNA was reverse-transcribed into cDNA using a high capacity
cDNA reverse transcription kit (Applied Biosystems, Foster City, CA).
cDNA was stored at−80 °C prior to PCR. Gene expression was quanti-
ﬁed by real-time quantitative PCR using iQ SYBR Green Supermix
(BIO-RAD, Hercules, CA). DNA ampliﬁcation was carried out using an
Icycler iQ5 (BIO-RAD, Hercules, CA) and product detection was per-
formed by measuring the binding of the ﬂuorescent dye SYBR Green I
to double-stranded DNA. The following primer sets were provided by
QIAGEN (Valencia, CA): COX-2 (QT00040586), IL-1R1 (QT00081263),
NF-κB p50 (QT00154091), NF-κB p65 (QT00149415), β-Actin (QT016
80476), GAPDH (QT00079247), and PPIA (peptidylpropyl isomerase
A; QT01866137). The relative quantities of target gene mRNA against
an internal control, β-Actin/GAPDH/PPIA RNA, were measured by
following a ΔCt method employing an ampliﬁcation plot (ﬂuorescence
signal vs. cycle number). The difference (ΔCt) between themean values
in the triplicate samples of target gene and those of β-Actin/GAPDH/
PPIA RNA was calculated by iQ5 Optical System Software version 2.0
(BIO-RAD, Hercules, CA) and the relative quantiﬁed value (RQV) was
expressed as 2−ΔCt. Semi-quantitative PCR was performed to examine
128 S. Lamy et al. / Biochimica et Biophysica Acta 1853 (2015) 126–135ampliﬁcation products and amplicons resolved on 1.8% agarose gels
containing 1 mg/mL ethidium bromide.
2.5. Cytotoxicity assays
The sensitivity of U-87 MG cells to luteolin was determined in vitro
by using the WST-1 assay (Roche Diagnostics, Montreal, QC). Brieﬂy,
after co-treatment of cells with IL-1β and luteolin for 24 h, U-87 MG
cells were exposed to 10 μL of the tetrazolium salt WST-1 reagent. The
soluble formazan dye produced by metabolically active cells was moni-
tored for 60 min at 37 °C. The absorbance at 450 nm was measured
using a SpectraMax Plus reader (Molecular Devices, Sunnyvale, CA).
2.6. Fluorimetric caspase-3 assay
U-87 MG cells were treated for 24 h with luteolin in the presence or
absence of 50 ng/mL IL-1β. Cells were collected, washed in cold PBS and
lysed in Apo-alert lysis buffer (Clontech, Palo Alto, CA) for 20min at 4 °C
and the lysates were clariﬁed by centrifugation at 16,000 ×g for 20min.
Caspase-3 activity was determined by incubation with 50 mM of the
caspase-3-speciﬁc ﬂuorogenic peptide substrate acetyl-Asp-Glu-Val-
Asp-7-amino-4-triﬂuoromethylcoumarin (Ac-DEVD-AFC) in assay buff-
er [50 mM Hepes-NaOH (pH 7.4), 100 mM NaCl, 10% sucrose, 0,1% 3-
[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate, 5 mM
DTT and 1 mM EDTA] in 96-well plates. The release of AFC was moni-
tored for at least 30 min at 37 °C on a ﬂuorescence plate reader (Molec-
ular Dynamics) (λex = 400 nm, λem= 505 nm).
2.7. Transfection method and RNA interference
U-87 MG cells were transiently transfected with 20 nM siRNA
against IL-1R1 (SI00017584), NF-κB p50 (SI01326990), NF-κB p65
(SI01399622) or scrambled sequences (AllStar Negative Control
siRNA, 1027281) using Lipofectamine 2000 transfection reagent
(Invitrogen, CA). Cells were treated for 24 h with luteolin in the pres-
ence or absence of 50 ng/mL IL-1β. Small interfering RNA andmismatch
siRNA were synthesized by QIAGEN and annealed to form duplexes.
2.8. Immunoﬂuorescence
U-87 MG cells were grown on coverslips to 60% conﬂuence, treated
for 24 hwith 15 μM luteolin and then incubatedwith 50 ng/mL IL-1β for
10 min. Following this, cells were incubated in 10% formalin phosphate
buffer for 20 min, followed by incubation in permeabilization buffer
(0.5% Triton X-100 in PBS) for 5 min and then blocked in 1% BSA and
0.1% NaN3 in PBS for 1 h. The coverslips were incubated 1 h with anti-
NF-κB p65 (1:500) in 1% BSA, 0.1% NaN3 in PBS. After three PBS washes,
the cells were incubated for 1 h with Alexa Fluor® 488 donkey anti-
rabbit secondary antibody (1:200) in 1% BSA and 0.1% NaN3. The cover-
slips were then washed 3 times in PBS and laid down on microscope
slides using ProLong Gold Antifade Reagent from Invitrogen (Carlsbad,
NM). The samples were viewed under a confocal microscope using
NIS Elements and Viewer and analyzed with ImageJ software.
2.9. Statistical analysis
Statistical analyses were assessed with Student's t-test when one
group was compared with the control group. To compare two or more
groups with the control group, one-way analysis of variance (ANOVA)
with Dunnett's post hoc test was used. To investigate a signiﬁcant inter-
action between two curves (control group versus treated group), a
Tukey's post hoc test and a trend analysis were performed. Differences
with p b 0.05 were considered signiﬁcant. All statistical analyses and
graphs were performed using GraphPad Prism version 5.0b for Macin-
tosh (GraphPad Software, San Diego, CA, USA; www.graphpad.com).
The nonlinear regression analysis was used for ﬁtting curves to data.3. Results
3.1. Biphasic effects of luteolin on IL-1β-induced COX-2 gene and protein
expression in human glioblastoma cells
Since modulations in COX-2 expression control brain tumor devel-
opment within chronic inﬂammation [9,10], we ﬁrst examined the ef-
fect of luteolin on IL-1β-induced COX-2 expression in U-87 MG cell
line. We choose this model because Taniura et al. [6] demonstrated
that COX-2 expression was remarkably increased in U-87 MG cell line
compared to other glioma cell lines tested (A172, T98G). U-87 MG
cells were serum-starved in the presence of 50 ng/mL IL-1β and various
concentrations of luteolin for 24 h. Under these conditions, IL-1β alone
caused a marked increase in COX-2 protein expression in U-87 MG
(Fig. 1A). This induction was potentiated by luteolin treatment at con-
centrations ranging between 1–15 μM and decreased at higher concen-
trations (20–50 μM) (Fig. 1A). These results show that the peak of
synergistic IL-1β/luteolin stimulation of COX-2 expression was reached
at 15 μM, but was completely inhibited at 25 μM(Fig. 1B). A biphasic ef-
fect of luteolin on IL-1β-induced COX-2 expressionwas also observed at
the transcriptional level (Fig. 1C). Such biphasic effects of luteolin were
not observed when COX-2 expression was induced with the tumor-
promoting agent PMA, where a concentration-dependent inhibition of
COX-2 protein expression by luteolinwas observed (Fig. 1D). This result
thus suggests that luteolin affects downstream IL-1β receptor-mediated
signaling.
3.2. Luteolin inhibits IL-1β-induced downstream signaling events in human
glioblastoma cells
We next evaluated the effect of luteolin treatment on IL-1β-induced
activation of NF-κB and MAPK signaling pathways known to up-
regulate COX-2 expression [15,30]. U-87 MG cells were pre-treated for
24 h with various concentrations of luteolin in serum-free medium,
and then stimulated with 50 ng/mL IL-1β for 5 min. Protein expression
and phosphorylation status of downstream signaling intermediates
targeted by luteolin were assessed by immunoblotting using speciﬁc
antibodies. Pretreatment with luteolin resulted in a concentration-
dependent inhibition of IL-1β-induced phosphorylation of IκB, NF-κB
p65, ERK and JNK with half-maximal inhibition concentrations (IC50)
of 21 μM, 18 μM, 11.1 μM and 0.7 μM, respectively (Fig. 2A–D). Interest-
ingly, the IC50 values obtained for the inhibition of MAPK signaling
pathways by luteolin were low compared to those obtained for NF-κB,
suggesting that the MAPK cascade may be predominantly involved
in the synergistic IL-1β/luteolin effects on COX-2 expression, while
NF-κB signaling may possibly be involved in the diminished IL-1β-
induction of COX-2 at higher luteolin concentrations. Moreover, the
fact that low concentrations of luteolin appeared to increase the phos-
phorylation of NF-κB indicates a possible translocation of p65 subunit
to the nucleus, which correlated with the induction of COX-2.
3.3. Effect of luteolin on human glioblastoma cell viability
To determine whether the anti-IL-1β inhibitory effects of luteolin
observed at higher concentrations (N20 μM) were due to cytotoxicity,
we next assessed the effect of this compound on IL-1β-induced death/
survival signaling pathways. U-87 MG cells were treated with various
concentrations of luteolin in serum-free medium for 24 h, and then
stimulated with 50 ng/mL IL-1β for 5 min. Luteolin caused a
concentration-dependent decrease in phosphorylated AKT, while the
amount of unphosphorylated AKTwas unaltered (Fig. 3A). These effects
were observed in the basal conditions and were signiﬁcantly poten-
tiated in the presence of IL-1βwith the IC50 value for luteolin decreasing
from 1.8 μM to 0.6 μM. To assess whether luteolin affects GRP78,
survivin or caspase-3 protein levels, U-87 MG cells were serum-
starved in the presence of 50 ng/mL IL-1β and various concentrations
Fig. 1. Effect of luteolin on IL-1β-induced COX-2 gene and protein expression in human glioblastoma cells. U-87MG cells were serum-starved in the presence of various concentrations of
luteolin containing (or lacking) 50 ng/mL IL-1β for 24 h. (A) Cells were lysed and the levels of COX-2 protein expressionweremonitored by immunoblotting. Immunodetections obtained
from representative experiments are shown. (B) The band intensities were analyzed by scanning densitometry using ImageJ software and the quantiﬁcation of three independent
experiments is shown. Values aremeans± SEM (**p b 0.01 and ***p b 0.001 versus IL-1β alone). For each sample, the COX-2 level was normalized for GAPDH. (C) Total RNAwas isolated
from conditions described above, cDNA synthesis, and qPCR performed to assess COX-2 gene expression. Values are means ± SEM of three independent experiments (*p b 0.05 and
***p b 0.001 versus basal control alone). (D) U-87 MG cells were serum-starved in the presence of various concentrations of luteolin containing (or lacking) 1 μM PMA for 24 h. A
representative Western blot depicting COX-2 levels, and GAPDH as a loading control, is shown.
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expression while it triggered both caspase-3 cleavage and GRP78 ex-
pression. Again, these effects were potentiated by the presence of IL-
1β, indicating that all of these responses were possibly triggered
through IL-1R1-mediated signaling. In order to strengthen these results,
we measured the enzymatic activation of caspase-3 under the same
conditions. Luteolin induced caspase-3 activity in a concentration-
dependent manner, indicating that apoptosis signaling was involved
(Fig. 3B). Furthermore, statistical analysis conﬁrmed that the two curves
at lower concentrations had similar effects on the induction of caspase-
3 activity; however, at luteolin concentrations above 15 μM, the IL-1β-treated cells began to behave differently than IL-1β-untreated cells sug-
gesting that, above this concentration, IL-1β-mediated signaling poten-
tiated the action of luteolin towards the apoptosis pathway. Consistent
with this result, the highly sensitive WST-1 assay showed that the
viability of the cells treated with ≥15 μM luteolin signiﬁcantly de-
creased in a concentration-dependent manner with an IC50 of 19.2 μM
(Fig. 3B) indicating a mode of cell death by apoptosis. Since MAPK sig-
naling pathway mediates growth factor-dependent cell survival [31],
we examined whether ERK and JNK were involved in survival of U-87
MG cells. As shown in Fig. 3C, the treatment of cells with the MEK
inhibitor U0126 or the JNK inhibitor SP60012 inhibited both AKT
Fig. 2. Luteolin inhibits IL-1β-induced downstream signaling events in human glioblastoma cells. U-87MG cells were serum-starved in the presence of various concentrations of luteolin
for 24 h. Then cells were stimulated with 50 ng/mL IL-1β for 5 min. After these treatments, the phosphorylated forms of (A) IκB, (B) NF-κB, (C) ERK, or (D) JNK, along with their total
protein levels, were monitored by immunoblotting. Immunodetection obtained from representative experiments is shown (top panels). The band intensities were analyzed by
densitometry using ImageJ software and expressed in arbitrary units as a ratio of levels of phosphorylated protein to those of the total protein to correct for variation in the amount of
protein (bottom panel). For pIκB, each band was normalized for GAPDH. The relative levels of phosphorylated protein were also normalized to those seen in IL-1β control (value =
100). Values are means ± SEM of three independent experiments (*p b 0.05, **p b 0.01 and ***p b 0.001 versus IL-1 alone).
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3 activation. These data supported the implication of ERK and JNK acti-
vated by IL-1β as survival signals in U-87 MG cells.
3.4. IL-1 receptor-mediated events are required in the luteolin inhibition of
IL-1β-induced COX-2 expression
In order to elucidate the mechanisms underlying the synergistic IL-
1β/luteolin-induction of COX-2, we next explored whether IL-1R1-
mediated events were involved. IL-1R1 blockade was performed with
the use of another member of the IL-1 family, the antagonist IL-1Ra.
U-87 MG cells were serum-starved in the presence of 50 ng/mL IL-1β
containing (or lacking) 15 μM of luteolin or 500 ng/mL IL-1Ra for 24 h.
While IL-1Ra itself had no effect on COX-2 under these conditions, it
signiﬁcantly reduced the IL-1β/luteolin-induction of COX-2 gene ex-
pression (Fig. 4A). The requirement for IL-1R1 was conﬁrmed through
gene silencing strategies showing that the effects of IL-1β alone or
combined IL-1β/luteolin on COX-2 protein expression were greatly
attenuated by the gene silencing (Fig. 4B). Interestingly, while effective
silencing of IL-1R1 also signiﬁcantly reduced COX-2 transcription in IL-
1β/luteolin-treated cells (Fig. 4C, bottom panel), IL-1β/luteolin was
able to reduce IL-1R1 transcription in siScrambled control cells
(Fig. 4C, top panel). This suggests that part of the synergistic IL-1β/luteolin-mediated effects on COX-2 transcription involves IL-1R1 and
part involves IL-1R1-induced downstream signaling. However, even if
IL-1R1 gene silencing completely abrogated IL-1β-induced COX-2,
luteolin was still able to trigger some COX-2 gene and protein expres-
sions (panels B–C), although to reduced levels in IL-1R-depleted cells,
indicating the requirement of IL-1R-independent mechanisms. The
fact that IL-1Ra did not reduce IL-1β signal except if luteolinwas present
(Fig. 4A) supports this observation.3.5. Gene silencing of NF-κB p65, but not of NF-κB p50, abrogates IL-1β-
mediated induction of COX-2 expression
Among the nuclear factors that regulate COX-2 transcription, theNF-
κB p50 and NF-κB p65 transcription factors were examined to deter-
mine if they were involved in the synergistic IL-1β/luteolin-induction
of COX-2. Gene silencingwasperformed inU-87MGcells and speciﬁcity
of knockdown was validated (Fig. 5A). While IL1-β or IL-1β/luteolin
triggered COX-2 protein expression under control (siScrambled) condi-
tions, COX-2 expression was completely abrogated only in those cells in
which NF-κB p65 gene expression was speciﬁcally downregulated
(Fig. 5B). The involvement of NF-κB p65 was further correlated at the
transcriptional level control of COX-2, and this conﬁrms that its absence
Fig. 3. Luteolin modulates IL-1β-induced apoptotic and survival signaling pathways in human glioblastoma cells. (A) U-87 MG cells were serum-starved in the presence of various
concentrations of luteolin containing (or lacking) 50 ng/mL IL-1β for 24 h except for AKT phosphorylation where IL-1βwas added to the cells for 5 min after cell treatment with luteolin.
RepresentativeWestern blots (from three independent experiments) are shown for the expression of pAKT, AKT, GRP78, survivin, caspase-3, cleaved caspase-3 andGAPDH.Western blots
were quantiﬁed and bandswere corrected for their speciﬁc protein loading control, AKT for pAKT, GAPDH for the others. The relative levels of phosphorylatedAKTwere also normalized to
those seen in IL-1β control (value= 1). (B) Extracts from control and treated cells were used to determine DEVDase (caspase-3) activity (top panel). Cell viability was assessed byWST-1
assay (bottom panel), as described in the Materials and methods section. Values are means ± SEM of three independent experiments performed in triplicate (***p b 0.001 versus IL-1β
alone). Statistical signiﬁcance of differences between control and IL-1βwas calculated by one-way analysis of variance followed by Tukey's test and a trend analysis (*p b 0.05). (C) U-
87 MG cells were serum-starved in the presence or not of 35 μM of luteolin, 10 μM of U0126, or 10 μM of SP60012 for 24 h with 50 ng/mL IL-1β or before adding IL-1β for 5 min.
Representative Western blots (from two independent experiments) are shown.
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(Fig. 5C).
3.6. Luteolin potentiates IL-1β-mediated NF-κB p65
translocation to the nucleus
In order to further investigate the role of NF-κB p65 and its role in
the transcriptional control of COX-2 in the nucleus, we pre-treated U-87 MG cells with or without 15 μM luteolin, stimulated the cells with
IL-1β for up to 15 min, and monitored the protein expression of NF-κB
p65 and of lamin A/C protein in the nuclear fractions (Fig. 6A, left
panel). While the expression of lamin A/C remained constant under
both control and luteolin-treated conditions, NF-κB p65 expression
increased in IL-1β-treated cells, and this effect was potentiated at 10–
15 min when the cells were pre-incubated with luteolin (Fig. 6A, right
panel). Confocal microscopic images of immunoﬂuorescence staining
Fig. 4. IL-1 receptor antagonist and IL-1 receptor gene silencing affect IL-1β/luteolin-induced COX-2 gene and protein expression. (A) U-87MG cells were serum-starved in the presence of
50 ng/mL IL-1β containing (or lacking) 15 μM of luteolin or 500 ng/mL IL-1Ra for 24 h. Total RNA was isolated, cDNA synthesis, and qPCR performed to assess COX-2 gene expression.
Values are means ± SEM of three independent experiments (*p b 0.05 versus IL-1β alone). (B-C) U-87 MG cells were transiently transfected with siRNA against IL-1R (siIL-1R1) or
with a scrambled sequence (siScrambled) as described in the Materials and methods section. (B) Representative Western blots are shown for the expression of COX-2, and GAPDH as
a loading control. (C) Total RNA was extracted and qRT-PCRwas used to assess IL-1R1 and COX-2 gene expression upon treatment with 50 ng/mL IL-1β or 15 μM luteolin for 24 h. Values
are means ± SEM of three independent experiments (**p b 0.01 and ***p b 0.001 versus IL-1β alone).
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tion of NF-κB in IL-1β/luteolin-treated cells (Fig. 6C). Altogether, this is
the ﬁrstmolecular evidence that explains how increased COX-2 expres-
sion is triggered by low concentrations of luteolin in the presence of IL-
1β.
4. Discussion
Our current study sheds further light on the anti-inﬂammatory and
potential chemopreventive properties of luteolin [24]. We document
for the ﬁrst time that, within a pathological inﬂammatory environment
such as thatmimicked by the action of PMAor IL-1β, luteolin concentra-
tions higher than 15 μMcan exert signiﬁcant inhibition of IL-1β-induced
COX-2 expression in U-87 glioblastoma cells. This observation is rele-
vant to the physiological plasma level of 10–20 μM [32,33] and of
14 μM after oral gavage with 50 μmol/kg of luteolin administration in
rats [34].
Chemopreventive assessment of luteolin has also established this
class of diet-derived molecule as a potent signal transduction inhibitor
[35], and this is supported by our current data which demonstrate
that luteolin inhibited IL-1β-induced phosphorylation of JNK, ERK, IκB,
and NF-κB. Interestingly, the IC50 values for luteolin inhibition against
IL-1β signaling ranged from 0.7–11.1 μM for the inhibition of ERK and
JNK pathways, while IC50 values ranged from 18–21 μM for IκB and
NF-κB signaling. Our study is therefore the ﬁrst to document the differ-
ential effect of luteolin at sub-physiological concentrations on MAPK
versus NF-κB signaling pathways triggered by IL-1β. Intriguingly, we
also observed biphasic effects of luteolin on IL-1β-induced COX-2 ex-
pression whereas this effect was not observed in the inhibition of
pAKT, survivin, or caspase-3 cleavage. More speciﬁcally, low concentra-
tions of luteolin (≤15 μM) clearly potentiated IL-1β-induction of COX-2
expression, while higher concentrations (N15 μM) of luteolin exerted
anti-IL-1β effects. The synergistic IL-1β/luteolin effects at low luteolin
concentrations could be consequent to a rapid (less than 10 min) in-
crease in NF-κB p65 translocation processes from the cytosol to the nu-
cleus which leads to elevated COX-2 mRNA levels. This is correlated
with the induction of the phosphorylation of NF-κB p65 by IL-1β/luteolin observed in our study indicating an accumulation of the p65
subunit. Since qRT-PCR analysis of the p50 and p65 genes conﬁrmed
their presence in U-87 MG cells, it is possible that not only p65/p50
heterodimers were localized in the cytoplasm, but also p65/p65 homo-
dimers [36]. Western blotting analysis of the expression of these sub-
units showed also that the gene silencing of NF-κB p65, but not of NF-
κB p50, abrogated IL-1β-mediated induction of COX-2 expression.
These results indicate that p50 is not involved in COX-2 upregulation
by IL-1β in U-87MG cells. Gu et al. [37] reported differential alterations
of NF-κB to oxidative stress in basal forebrain primary cultures and that
NF-κB activation appeared to mostly affect p65 translocation to the
nucleus but not that of the p50 subunit. They observed that there was
a distinctive translocation of NF-κB p65 subunits in response to extrinsic
hydrogen peroxide, nerve growth factor or TNF-α stimuli, without any
corresponding changes in the distribution of p50. Consistent with
these data, Liu et al. [38] reported that PIAS1 (protein inhibitor of acti-
vated STAT1), an important negative regulator of NF-κB, interacted
with p65 but not p50 subunit of NF-κB. The synergistic IL-1β/luteolin
effects at low luteolin concentrations could also be explained by the re-
quirement of IL-1R-independent mechanisms in the action of luteolin.
Since IL-1R1 gene silencing completely abrogated IL-1β-induced COX-
2, while luteolin was still able to trigger some COX-2 protein expression
although to a reduced level in IL-1R-depleted cells. This conclusion is ﬁ-
nally supported by our owndatawhere N90% gene silencing of IL-1R1 at
best reduced by only ~50% IL-1β-mediated COX-2 transcriptional regu-
lation. More importantly, luteolin was able to further reduce COX-2
transcript levels to N70% through either the residual gene expression
of IL-1R1 upon its silencing or through IL-1R1-independent mecha-
nisms. Interestingly, effects of IL-1Ra independent of the activation of
IL-1R1 have been demonstrated and reported elsewhere [39]. Although
speculative, such mechanisms may involve IL-1Ra binding to recently
identiﬁed members of the IL-1R family, which include TIR8/SIGIRR, IL-
1RAcPb, TIGIRR-1 and IL-1RAPL [40].
Interestingly, synergistic induction of GRP78, which plays an essen-
tial role in the progression and therapeutic resistance of many cancers
[41], was found to be a cellular response to stress and was modulated
at luteolin concentrations between 10–20 μM. This increase in GRP78
Fig. 5.NF-κB p65, but not NF-κB p50, gene silencing reverses the effect of luteolin on IL-1β-
mediated induction of COX-2 expression. U-87MG cells were transiently transfectedwith
siRNA against NF-κB p50 (sip50), NF-κB p65 (sip65) or with a scrambled sequence
(siScrambled) as described in the Materials and methods section. (A) Total RNA was ex-
tracted and qRT-PCR was used to assess NF-κB p50 and NF-κB p65 gene expression in
the transfectedU-87MG cells. Values aremeans±SEMof three independent experiments
(***p b 0.001 versus IL-1β alone). (B) Representative Western blots are shown for the
expression of COX-2 with GAPDH as a loading control. (C) Total RNA was extracted and
qRT-PCR was used to assess COX-2 gene expression in the siScrambled and sip65-
transfected U-87 MG cells upon treatment with 50 ng/mL IL-1β or 15 μM luteolin for
24 h. Values are means ± SEM of three independent experiments (***p b 0.001 versus
IL-1β alone).
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suggest that low luteolin concentrations are efﬁcient in triggering endo-
plasmic reticulum (ER) stress in inﬂammatory settings. Similarly, en-
hanced ER stress was recently shown to restore GRP78 trafﬁcking to
the cell surface, thereby sensitizing cancer cells to apoptosis [42]. At
higher concentrations of luteolin, the increase in GRP78 protein was di-
minished in a concentration-dependentmanner and thiswas correlated
with an increase in caspase-3 protein cleavage. In linewith this, our dataalso show that IL-1β alone was inefﬁcient at cleaving and inducing
caspase-3, while cleavage and activation of caspase-3 and cell death
were signiﬁcantly potentiated in the presence of luteolin in a
concentration-dependent manner (15–50 μM). The fact that luteolin
inhibited AKT phosphorylation in both basal conditions and with IL-1β
treatment is consistentwith a previous report indicating that the inhibi-
tion of constitutive AKT activation induced apoptosis in various human
pancreatic carcinoma cell lines [43].
We showed that luteolin preferentially inhibited the MAPK path-
way, with a lower IC50 value than seen with the NF-κB pathway. This
differential inhibitory effect could be explained by the involvement of
each pathway in the cellular stress response [44,45]. It was reported
that signal transduction from the ER to the cell nucleus could be medi-
ated by a signaling cascade similar to the plasma membrane-initiated
cell signaling such asMAPK [46,47]. Members of theMAPK family phos-
phorylate a number of transcription factors with subsequent induction
of inﬂammatory gene expression such as COX-2 [30]. It may be
envisioned that theMAPK pathway is involved in the early adaptive cel-
lular stress response during which COX-2 gene and protein expressions
were signiﬁcantly increased, and that simultaneously activates luteolin-
mediated NF-κB nuclear translocation,which is required to trigger COX-
2 expression. Consequent increases in prostaglandin E2may, thereafter,
contribute to important paracrine biological activities related to thepro-
duction of immune-regulatory cytokines that allow cancer cells to try to
initially escape the immune system [48] or to inhibit tumor cell apopto-
sis [49]. Since multiple levels of cross-talk exist betweenmitogenic Ras/
MAPK and survival PI3K/AKT pathways [50], both pathways can there-
fore activate or inhibit each other. It is noteworthy that MAPK pathway
inhibition by low concentrations of luteolin could prevent the induction
of escape mechanisms to survival pathways (PI3K/AKT) inhibition, and
consequently, sustain the downregulation of expression of survivin and
AKT phosphorylation, and initiate the cellular apoptotic machinery. The
fact that MAPK synthetic inhibitors affected also these proteins in our
experimental conditions supports the implication of ERK and JNK path-
ways in survival of U-87 MG cells.
The synergistic and biphasic inductions of COX-2 and GRP78 ob-
served in our study seem to be performed through a possible common
IL-1β/luteolin responsive mechanism. Such behavior is not unique to
luteolin, since Young et al. [51] also reported a biphasic effect for the
polyacetylene falcarinol, isolated from carrots, which induced prolifera-
tive and apoptotic characteristics in a human colon carcinoma cell line
at low (b20 μM) and high (N10 μM) concentrations, respectively. More-
over, phytochemicals such as luteolin, can also function either as anti-
oxidant or as pro-oxidant molecules [24]. Oxidative stress has been
involved in various neurological disorders and in the central nervous
system (CNS) [52] and there is a positive association between the pres-
ence of glioblastoma multiforme and oxidative stress [53]. It can there-
fore be envisioned that the chemopreventive properties of luteolin,
speciﬁcally within inﬂammatory and oxidative stress settings such as
those triggered by IL-1β (this study, [54]), take place at low concentra-
tions due to its ability to induce a state of oxidative stress as reﬂected by
subsequent induction of COX-2 and GRP78 expressions. Such mecha-
nisms were previously documented where chemopreventive agents in-
duced COX-2 in human colon and pancreatic cancer cell lines [55].
Induction of oxidative stress by chemopreventive agents in cancer
cells was suggested to lead to COX-2 overexpression and to COX-2-
independent cell death [55]. The increased COX-2 expression observed
in our study is also in good agreementwith a previous report indicating
a similar COX-2 response by ﬂavonoids to lipopolysaccharide treatment,
a condition also known to trigger inﬂammation in enterocytes [56].
Consistent with our data, they also reported a downregulation of COX-
2 under conditions of high stress, indicating differential effects of
ﬂavonoids in inﬂammatory settings. Therefore, understanding whether
and how luteolin's intracellular redox state regulation activity is
involved in its cellular effects will be essential to evaluating its over-
all potential as an anticancer agent. Because luteolin exhibits slow
Fig. 6. Effect of luteolin on IL-1β-induced NF-κB translocation to the nucleus. (A) U-87MG cells were serum-starved in the presence (or absence) of 15 μM luteolin for 24 h, followedwith
50 ng/mL IL-1β stimulation for the indicated time. Nuclear cell fractions were prepared and submitted toWestern blot analysis using antibodies against NF-κB p65, lamin A/C as a loading
control. RepresentativeWestern blots from at least three independent experiments are shown (left panel) and were quantiﬁed (right panel). (B) U-87MG cells were seeded on coverslips
for immunoﬂuorescence and serum-starved in the presence (or absence) of 15 μM luteolin for 24 h. Then cells were stimulatedwith 50 ng/mL IL-1β for 10min. The coverslips were ﬁxed
and incubated with anti-NF-κB p65 antibody. NF-κB p65-stained cells were then visualized using a ﬂuorescence microscope. Representative images from two independent experiments
are shown. (C) NF-κB p65 localized in the nucleus was quantiﬁed. Values are means ± SEM of two independent experiments (**p b 0.01 and ***p b 0.001).
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tissues [57], it is thus tempting to speculate that low concentrations of
luteolin are as beneﬁcial as higher concentrations and may provide a
“metronomic-chemoprevention”-like inhibitory effect on COX-2 for
preventing cancer development.
Clinically, increased plasma levels of surrogate markers of IL-1β-
mediated CNS inﬂammation were found to correlate with fatigue,
sleep disturbance, and cognitive difﬁculties in cancer patients exposed
to cytotoxic chemotherapeutic agents [58]. Interestingly, preclinical
work suggests that IL-1β-mediated CNS inﬂammation may cause
these cancer treatment-related symptoms by altering hypothalamic
and hippocampal functioning, which implies that luteolin-based phar-
macologic targetingwill require access to the brain through the vascular
endothelium compartment. Evidence suggests that ﬂavonoids generally
can indeed penetrate the blood–brain barrier (BBB) [59–62]. It was re-
cently reported that peripherally administered luteolin freely penetrat-
ed the BBB and entered the brain in a mouse model of Alzheimer's
disease [63]. Thus, it is reasonable to predict that circulating luteolin
may have access to the microglial cell compartment and that, although
speculative, proper consumption of phytochemicals such as luteolin
may help reduce the IL-1β-mediated inﬂammatory processes and pre-
vent these symptoms from occurring in cancer patients.
The fact that only 5–10% of all cancer cases are due to genetic defects
and that the remaining 90–95% are due to environment and lifestyle
clearly provides opportunities for preventing cancer [64]. Overall, our
results provide evidence of the pleiotropic actions of luteolin as a signal
transduction inhibitor, an anti-inﬂammatory, and proapoptotic agent,
and shed light on new mechanisms supporting its physiological bene-
ﬁts. Consequently, our ﬁndings could help in the promotion of new
diet strategies to prevent brain tumor-associated neuroinﬂammation.Acknowledgements
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